[212Pb]Pb-DOTAM-MAM279

Lead-212 DOTAM-MAM279 radiopharmaceutical targeting DLL3 · Molecular Partners AG

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for [212Pb]Pb-DOTAM-MAM279, covering 2026-04-08 to 2026-04-08. Get the full timeline:

Most recent: Clinical Trial Update: Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors [Phase 1, Phase 2]

See pricing